Scientists are developing a range of second-generation covid vaccines that aim to extend protection against many different virus mutations, the Guardian said. Candidates include one version that may provide protection against many different virus modifications. Other researchers are studying the response to a vaccine aimed at preventing the spread of the disease.
Research on new covid changes
Other projects include research into the creation of multiple vaccines that can each treat different types of viruses. It would be administered as a single injection in a similar way to other vaccines given to humans. Currently, covid vaccines are designed to prevent infected people from becoming ill. It is not yet known how effective they are in preventing viruses that can be transmitted.
Read: Thousands of Americans experience ‘hard’ reactions to COVID vaccines: CDC Report
Read: Pfizer withdrawal application for COVID-19 vaccine emergency use permit in India
Professor Jonathan Ball, a pathologist at the University of Nottingham, said, “There is no evidence that any of the newly emerged virus variants are causing a serious infection than the original virus”. He said, “But there is evidence that some of these new changes may improve infection and thus spread in numbers with complementary immunity after a natural or vaccine infection”. One possible solution is a vaccine that is now being developed by a team of scientists including Ball.
Read: COVID-19: Pfizer-BioNTech Their vaccine says it is effective against UK, South African changes
Read: The UK Health Minister warns that vaccines can work just as well on Covid-19 modifications
The project, which also involves the immunology firm Scancell and researchers at the University of Nottingham Trent, has reached a stage where manufacturing of the new vaccine has begun. Member stated that it was hoped that clinical trials of the vaccine would be launched shortly. He said, “The plasmid which is the basis of the vaccine has already been used in other medical treatments and is recovering well in patients. So, hopefully we can go ahead. progress with relatively rapid clinical trials “.
Scientists at the University of Bristol have begun developing a vaccine that can stimulate antibodies in a person’s nose and throat. Adam Finn, Professor of Pediatrics at Bristol School of Medicine, University of Bristol, said, “This is the way the virus affects a person, so if you could focus specifically on generating antibodies in the upper airways to help prevent the virus from infecting. someone or from being handed over. ”“ Of course, you would be creating an anti-viral equivalent of those United Nations blue-helmet soldiers who control zones of war and prevent attacks “, he said.